Guardion Health Sciences, Inc. (GHSI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Guardion Health Sciences, Inc. (GHSI) with AI Score 46/100 (Weak). Guardion Health Sciences, Inc. operates as a specialty health sciences company, focusing on medical foods, nutraceuticals, and medical devices for vision-related conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Guardion Health Sciences, Inc. (GHSI) Healthcare & Pipeline Overview
Guardion Health Sciences, Inc. develops and markets medical foods, nutraceuticals, and medical devices targeting vision health. The company's focus on macular pigment and optic nerve support differentiates it within the specialty healthcare sector, addressing specific needs in ophthalmology with products like Lumega-Z and GlaucoCetin.
Investment Thesis
Guardion Health Sciences operates in the niche market of vision-related medical foods, nutraceuticals, and devices. The company's focus on macular degeneration and glaucoma provides a targeted approach to address prevalent eye conditions. With a gross margin of 44.0%, GHSI demonstrates the potential for profitability as it scales its operations. Key growth catalysts include expanding the market reach of Lumega-Z and GlaucoCetin, as well as increasing adoption of its VectorVision line of medical devices. The company's online distribution channel through guardionhealth.com offers a direct-to-consumer approach, potentially improving margins and customer engagement. However, the company's small market capitalization and OTC listing present liquidity and regulatory risks. The P/E ratio of 26.14 suggests investors anticipate future earnings growth, but this also implies a higher valuation that needs to be justified by strong execution.
Based on FMP financials and quantitative analysis
Key Highlights
- Guardion Health Sciences operates in two segments: Medical Foods and Nutraceuticals, and Medical Devices, diversifying its revenue streams within the vision health market.
- The company offers Lumega-Z, a medical food designed to replenish and restore macular protective pigment, addressing a critical need in age-related macular degeneration.
- GlaucoCetin, a vision-specific medical food, supports and protects the mitochondrial function of optic nerve cells, targeting glaucoma patients.
- Guardion's VectorVision line includes devices like MapcatSF, CSV-1000, and CSV-2000, providing standardized vision testing solutions for eye doctors.
- The company distributes its products through e-commerce via guardionhealth.com, enabling direct-to-consumer sales and broader market access.
Competitors & Peers
Strengths
- Specialized product portfolio targeting vision health.
- Proprietary formulations for medical foods.
- Direct-to-consumer distribution channel.
- Established brand recognition in the vision care market.
Weaknesses
- Small market capitalization.
- Limited financial resources.
- Dependence on a small number of key products.
- OTC listing presents liquidity and regulatory risks.
Catalysts
- Ongoing: Expansion of Lumega-Z market reach through targeted marketing campaigns and partnerships with eye care professionals.
- Ongoing: Increased adoption of VectorVision devices in clinical trials, real-world vision evaluation, and industrial vision testing.
- Ongoing: Development and commercialization of ImmuneSF through existing e-commerce platform.
- Upcoming: Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
- Upcoming: Positive clinical trial results demonstrating the efficacy of Lumega-Z or GlaucoCetin.
Risks
- Potential: Competition from larger pharmaceutical and medical device companies with greater resources.
- Potential: Regulatory changes affecting the medical food and nutraceutical industries.
- Potential: Product liability claims related to the safety or efficacy of Guardion's products.
- Ongoing: Economic downturn affecting consumer spending on healthcare products.
- Ongoing: Risks associated with operating as an OTC-listed company, including limited liquidity and regulatory oversight.
Growth Opportunities
- Expansion of Lumega-Z Market Reach: Lumega-Z, a medical food designed to replenish and restore the macular protective pigment, has a significant growth opportunity within the aging population. The global market for AMD treatment is projected to reach billions of dollars. By increasing awareness and distribution of Lumega-Z through targeted marketing campaigns and partnerships with eye care professionals, Guardion can capture a larger share of this growing market. Timeline: Ongoing.
- Increased Adoption of VectorVision Devices: The VectorVision line of medical devices, including MapcatSF, CSV-1000, and CSV-2000, offers standardized vision testing solutions for eye doctors. By expanding the sales and marketing efforts for these devices, Guardion can increase their adoption in clinical trials, real-world vision evaluation, and industrial vision testing. The market for vision testing equipment is expected to grow. Timeline: Ongoing.
- Development and Commercialization of ImmuneSF: ImmuneSF, a nutraceutical formulation, represents a growth opportunity for Guardion in the broader health and wellness market. By leveraging its expertise in formulation and distribution, Guardion can commercialize ImmuneSF through its existing e-commerce platform and expand its product portfolio. The nutraceuticals market is expected to continue its growth trajectory. Timeline: Ongoing.
- Geographic Expansion: Guardion Health Sciences currently focuses on the United States market. Expanding its operations to international markets, such as Europe and Asia, represents a significant growth opportunity. By adapting its products and marketing strategies to local regulations and consumer preferences, Guardion can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Guardion can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the vision care industry or acquiring complementary businesses can accelerate Guardion's growth and strengthen its competitive position. Timeline: Ongoing.
Opportunities
- Expansion of Lumega-Z market reach.
- Increased adoption of VectorVision devices.
- Development and commercialization of new products.
- Geographic expansion into international markets.
Threats
- Competition from larger pharmaceutical and medical device companies.
- Regulatory changes affecting the medical food and nutraceutical industries.
- Product liability claims.
- Economic downturn affecting consumer spending on healthcare products.
Competitive Advantages
- Specialized product portfolio focused on vision health.
- Proprietary formulations for medical foods like Lumega-Z and GlaucoCetin.
- Established brand recognition in the vision care market.
- Direct-to-consumer distribution channel through guardionhealth.com.
About GHSI
Guardion Health Sciences, Inc., founded in 2009 and headquartered in San Diego, California, is a specialty health sciences company dedicated to developing and commercializing innovative products for vision health. The company operates through two segments: Medical Foods and Nutraceuticals, and Medical Devices. Its flagship product, Lumega-Z, is a medical food designed to replenish and restore macular protective pigment, crucial for maintaining healthy vision. GlaucoCetin is another key product, a vision-specific medical food formulated to support and protect the mitochondrial function of optic nerve cells and improve blood flow in the ophthalmic artery for patients with glaucoma. In addition to medical foods, Guardion Health Sciences offers a range of medical devices. These include MapcatSF, which measures macular pigment optical density, and the CSV-1000 and CSV-2000 devices, standardized contrast sensitivity testing tools used by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. These devices are marketed under the VectorVision name. The company also develops ImmuneSF, a nutraceutical formulation, and markets a portfolio of nutraceutical products under the NutriGuard brand. Guardion distributes its products through e-commerce via its online store, guardionhealth.com, expanding its reach to a broader customer base. Guardion Health Sciences aims to address unmet needs in the vision health market through science-backed products and technologies.
What They Do
- Develops and markets Lumega-Z, a medical food for macular pigment replenishment.
- Offers GlaucoCetin, a vision-specific medical food for optic nerve support in glaucoma patients.
- Provides MapcatSF, a medical device measuring macular pigment optical density.
- Manufactures and sells CSV-1000 and CSV-2000 devices for standardized contrast sensitivity testing.
- Develops ImmuneSF, a nutraceutical formulation.
- Markets a portfolio of nutraceutical products under the NutriGuard brand.
- Distributes products through e-commerce via guardionhealth.com.
Business Model
- Develops and sells medical foods targeting specific vision conditions.
- Manufactures and sells medical devices for vision testing and evaluation.
- Markets and distributes nutraceutical products for overall health and wellness.
- Generates revenue through direct-to-consumer sales via its online store, guardionhealth.com.
Industry Context
Guardion Health Sciences operates within the specialty drug and medical device industry, focusing on vision care. The market for age-related macular degeneration (AMD) and glaucoma treatments is substantial and growing, driven by an aging population and increased awareness of eye health. The competitive landscape includes both pharmaceutical giants and smaller, specialized companies. Guardion differentiates itself through its focus on medical foods and nutraceuticals, offering alternative or complementary approaches to traditional pharmaceutical interventions. The company's success depends on its ability to demonstrate the efficacy and safety of its products through clinical studies and real-world evidence.
Key Customers
- Patients with age-related macular degeneration (AMD).
- Patients with glaucoma.
- Eye doctors and optometrists using vision testing devices.
- Individuals seeking nutraceutical products for overall health and wellness.
Financials
Chart & Info
Guardion Health Sciences, Inc. (GHSI) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Feb 22, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
· Nov 20, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Aug 15, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Aug 14, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GHSI.
Price Targets
Wall Street price target analysis for GHSI.
MoonshotScore
What does this score mean?
The MoonshotScore rates GHSI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark Goldstone
CEO
Mark Goldstone serves as the CEO of Guardion Health Sciences, Inc. His background includes experience in managing and growing healthcare companies, with a focus on strategic planning and execution. He has a track record of driving revenue growth and improving operational efficiency. His expertise spans various aspects of the healthcare industry, including product development, marketing, and sales. Goldstone's leadership is focused on expanding Guardion's market presence and delivering innovative solutions for vision health.
Track Record: Under Mark Goldstone's leadership, Guardion Health Sciences has focused on expanding its product portfolio and strengthening its distribution channels. Key achievements include the continued development and commercialization of Lumega-Z and GlaucoCetin, as well as the expansion of the VectorVision line of medical devices. Goldstone has also overseen the company's efforts to enhance its e-commerce platform and increase direct-to-consumer sales.
GHSI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Guardion Health Sciences may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be subject to the same level of scrutiny. This can result in increased risks for investors due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Higher price volatility.
- Limited regulatory oversight.
- Verify the company's registration and compliance status with regulatory agencies.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Monitor trading activity and price volatility.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established product portfolio targeting vision health.
- Direct-to-consumer distribution channel through guardionhealth.com.
- Presence in the vision care market.
- Focus on medical foods and nutraceuticals.
What Investors Ask About Guardion Health Sciences, Inc. (GHSI)
What does Guardion Health Sciences, Inc. do?
Guardion Health Sciences, Inc. is a specialty health sciences company focused on developing and commercializing innovative products for vision health. The company operates in two segments: Medical Foods and Nutraceuticals, and Medical Devices. Its key products include Lumega-Z, a medical food designed to replenish and restore macular protective pigment, and GlaucoCetin, a vision-specific medical food formulated to support and protect the mitochondrial function of optic nerve cells. Additionally, Guardion offers a range of medical devices under the VectorVision brand for standardized vision testing.
What do analysts say about GHSI stock?
As of March 17, 2026, there is no readily available analyst consensus on Guardion Health Sciences (GHSI) due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include the P/E ratio of 26.14 and the gross margin of 44.0%. Growth considerations include the potential for expanding the market reach of Lumega-Z and GlaucoCetin, as well as increasing adoption of its VectorVision line of medical devices.
What are the main risks for GHSI?
The main risks for Guardion Health Sciences include competition from larger pharmaceutical and medical device companies, regulatory changes affecting the medical food and nutraceutical industries, and potential product liability claims. Additionally, as an OTC-listed company, GHSI faces risks associated with limited liquidity, financial disclosure, and regulatory oversight. An economic downturn could also affect consumer spending on healthcare products, impacting the company's revenue and profitability. Investors should carefully consider these risks before investing in GHSI.
What are the key factors to evaluate for GHSI?
Guardion Health Sciences, Inc. (GHSI) currently holds an AI score of 46/100, indicating low score. Key strength: Specialized product portfolio targeting vision health.. Primary risk to monitor: Potential: Competition from larger pharmaceutical and medical device companies with greater resources.. This is not financial advice.
How frequently does GHSI data refresh on this page?
GHSI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GHSI's recent stock price performance?
Recent price movement in Guardion Health Sciences, Inc. (GHSI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product portfolio targeting vision health.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GHSI overvalued or undervalued right now?
Determining whether Guardion Health Sciences, Inc. (GHSI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GHSI?
Before investing in Guardion Health Sciences, Inc. (GHSI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- OTC market data may be limited and subject to inaccuracies.